Connection

Kit Simpson to Quality-Adjusted Life Years

Back to Details
This is a "connection" page, showing publications Kit Simpson has written about Quality-Adjusted Life Years.
Kit Simpson
Connection Strength
1.144
Quality-Adjusted Life Years
  1. Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III. J Am Heart Assoc. 2017 May 08; 6(5).
    View in: PubMed
    Score: 0.139
  2. Cost-effectiveness analysis of annual Trichomonas vaginalis screening and treatment in HIV-positive women to prevent HIV transmission. Sex Transm Dis. 2014 Jun; 41(6):353-8.
    View in: PubMed
    Score: 0.113
  3. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics. 2013 May; 31(5):427-44.
    View in: PubMed
    Score: 0.105
  4. Economic analysis of secondary trial data. Prog Cardiovasc Dis. 2012 Jan-Feb; 54(4):351-6.
    View in: PubMed
    Score: 0.096
  5. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya. Value Health. 2011 Dec; 14(8):1048-54.
    View in: PubMed
    Score: 0.095
  6. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis. Adv Ther. 2009 Mar; 26(3):346-68.
    View in: PubMed
    Score: 0.079
  7. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther. 2009 Feb; 26(2):185-93.
    View in: PubMed
    Score: 0.078
  8. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials. 2008 Jul-Aug; 9(4):225-37.
    View in: PubMed
    Score: 0.075
  9. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Investig. 2007; 27(1):67-74.
    View in: PubMed
    Score: 0.068
  10. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Clin Drug Investig. 2007; 27(7):443-52.
    View in: PubMed
    Score: 0.068
  11. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig. 2007; 27(12):807-17.
    View in: PubMed
    Score: 0.068
  12. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest. 2003 Dec; 124(6):2087-92.
    View in: PubMed
    Score: 0.055
  13. Evaluating the quality of life associated with rifabutin prophylaxis for Mycobacterium avium complex in persons with AIDS: combining Q-TWiST and multiattribute utility techniques. Qual Life Res. 1995 Aug; 4(4):309-18.
    View in: PubMed
    Score: 0.031
  14. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-na?ve women of childbearing age. J Med Econ. 2014 Apr; 17(4):250-8.
    View in: PubMed
    Score: 0.028
  15. Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig. 2009; 29(10):635-46.
    View in: PubMed
    Score: 0.019
  16. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clin Drug Investig. 2008; 28(5):291-303.
    View in: PubMed
    Score: 0.018
  17. Economic decision analysis model of screening for lung cancer. Eur J Cancer. 2001 Sep; 37(14):1759-67.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.